Press Releases

New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC. Test has potential to outperform current screening modalities for early stage HCC within high risk populations.

Endowed Chair and Professor of Bioinformatics for the Department of Biological Chemistry at the University of California, Irvine's School of Medicine to Expand AI Expertise.

Researchers to Study the Helio Health Liquid Biopsy Cancer Test's Efficacy in Detecting Liver Cancer.

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of prominent business leader and Asia market expert, Samuel Tong, as Chief Executive Officer of Laboratory for Advanced Medicine's Chinese operations.

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Benjamin Oyler as Chief Operating Officer. He will lead Laboratory for Advanced Medicine's global business operations.

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Aarif Nakhooda as Chief Financial Officer. Mr. Nakhooda has more than 25 years of financial, commercial and operational experience with rapidly growing companies, including Amazon.

IRVINE, Calif., Dec. 3, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection test from a simple blood draw, today announced the appointment of Christopher DeRosa, MBA, an industry leader in medical insurance and reimbursement, to the company's Board of Directors.

IRVINE, Calif., Nov. 12, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that it will be presenting new data supporting its methylation-based liver cancer diagnostic test at The Liver Meeting® 2019 hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Boston from Nov. 8-12. AASLD selected Laboratory for Advanced Medicine's

Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Kenneth Chahine, Ph.D., J.D., as Chief Executive Officer and board member. He will succeed Founder Shu Li, Ph.D., who will continue to serve as Chairman of the company's Board of Directors.

IRVINE, Calif., Oct. 23, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Alan List, M.D., an internationally recognized and respected oncologist, President and Chief Executive Officer at Moffitt Cancer Center, to the company's Board of Directors.

Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company with innovative technologies for the early diagnosis of cancer, today announced that its Liver Cancer detection test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). The liquid biopsy blood test is designed to detect the presence of liver cancer, as early as Stage I, with high specificity and sensitivity.

Dr. Abou-Alfa, oncologist at Memorial Sloan Kettering; Dr. Gish, Medical Director of Hepatitis B Foundation; and Dr. Hoshida, Director of Translational Research in Liver Cancer at the University of Texas Southwestern Medical Center, bring liver cancer treatment expertise to company's board

Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced positive results from a new study that evaluated DNA methylation-based marker panel for early diagnosis of nasopharyngeal carcinoma (NPC). The data appear in an online abstract as part of the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4, in Chicago.

IRVINE, Calif., March 31, 2019 -- Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data at the American Association for Cancer Research (AACR) Annual Meeting at the Georgia World Congress Center in Atlanta, Georgia. The data demonstrate LAM's proprietary IvyGene Tests possess the ability to detect liver cancer with 95% sensitivity and...

IRVINE, Calif., Mar. 20, 2019 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, announced today a poster presentation titled “Circulating Cell-Free DNA Methylation Assay: Towards Early Detection of Multiple Cancer Types” will be presented at the American Association for Cancer Research (AACR) Annual Meeting.

IRVINE, Calif., Dec. 7, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data at the San Antonio Breast Cancer Symposium validating results from its discovery of biomarkers to accurately detect breast cancer.

IRVINE, Calif., Nov. 20, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the 2018 San Antonio Breast Cancer Symposium taking place Dec. 4 – 8 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This presentation will include new data supporting the ability of LAM’s IvyGene Platform to detect blood

IRVINE, Calif., Nov. 6, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data further validating results from its completed clinical study on liver cancer demonstrating the ability of LAM's novel DNA methylation-based biomarkers in detecting the presence of hepatocellular carcinoma (HCC) with 95% sensitivity and 97.5% specificity.

IRVINE, Calif., Oct. 23, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting taking place Nov. 7-11, 2018 in Washington, D.C.

IRVINE, Calif., July 12, 2018 /PRNewswire/ -- Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers, today announced that the Company has recently appointed Dr. Jinjie Hu as its Chief Regulatory Officer. Dr. Hu has over a decade of experience working directly with the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER).

IRVINE, Calif., June 4, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced that Justin Li, General Manager and Vice President of Finance, will present at the 2018 BIO International Convention, taking place on…

IRVINE, Calif., May 30, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced the commercialization of its revolutionary, non-invasive and highly accurate IvyGene test. IvyGene is designed to detect DNA methylation patterns consistent with…

IRVINE, Calif., May 17, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers, today announced that the Company has appointed Richard Brand as its Chief Financial Officer, effective immediately. Mr. Brand has more than…

IRVINE, Calif., March 14, 2018 — In an effort to help firefighters cover the high cost of cancer treatment as a result of the occupational risk of experiencing higher rates of certain types of cancer than the general U.S. population, Laboratory for Advanced Medicine (LAM) today announced the launch of…